CrystalGenomics, Inc. (083790.KQ)

KRW 2545.0

(0.99%)

EBITDA Summary of CrystalGenomics, Inc.

CrystalGenomics, Inc.'s latest annual EBITDA in 2023 was -42.79 Billion KRW , up 25.35% from previous year.
CrystalGenomics, Inc.'s latest quarterly EBITDA in 2024 Q2 was 313.55 Million KRW , down -72.67% from previous quarter.
CrystalGenomics, Inc. reported an annual EBITDA of -18.19 Billion KRW in 2022, down -23.12% from previous year.
CrystalGenomics, Inc. reported an annual EBITDA of -10.18 Billion KRW in 2021, down -173.22% from previous year.
CrystalGenomics, Inc. reported a quarterly EBITDA of -105.17 Million KRW for 2024 Q1, up 80.64% from previous quarter.
CrystalGenomics, Inc. reported a quarterly EBITDA of N/A for 2023 FY, up 25.35% from previous quarter.

Annual EBITDA Chart of CrystalGenomics, Inc. (2023 - 2013)

Historical Annual EBITDA of CrystalGenomics, Inc. (2023 - 2013)

Year	EBITDA	EBITDA Growth
2023	-42.79 Billion KRW	25.35%
2022	-18.19 Billion KRW	-23.12%
2021	-10.18 Billion KRW	-173.22%
2020	-3.35 Billion KRW	628.2%
2019	-30.11 Billion KRW	4.3%
2018	9.66 Billion KRW	3.17%
2017	-7.84 Billion KRW	1.92%
2016	561.48 Million KRW	6.06%
2015	-738.44 Million KRW	6.8%
2014	-6.37 Billion KRW	4.06%
2013	-8.08 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	313.55 Million KRW	-72.67%
2024 Q1	-105.17 Million KRW	80.64%
2023 FY	- USD	25.35%
2023 Q1	-3.52 Billion USD	-549.27%
2023 Q3	15.52 Billion USD	579.01%
2023 Q2	-3.24 Billion KRW	7.94%
2023 Q4	-19.99 Billion USD	-228.74%
2022 FY	- USD	-23.12%
2022 Q3	1.24 Billion USD	0.0%
2022 Q1	887.75 Million USD	22.2%
2022 Q4	783.68 Million USD	-37.04%
2021 Q4	726.45 Million USD	-37.95%
2021 FY	- USD	-173.22%
2021 Q1	897.52 Million USD	27.35%
2021 Q3	1.17 Billion USD	0.0%
2020 Q1	658.36 Million USD	11.63%
2020 Q3	1.15 Billion USD	0.0%
2020 Q4	704.77 Million USD	-38.84%
2020 FY	- USD	628.2%
2019 Q1	632.41 Million USD	30.72%
2019 Q3	892.81 Million USD	0.0%
2019 FY	- USD	4.3%
2019 Q4	589.77 Million USD	-33.94%
2018 Q4	483.79 Million USD	-41.68%
2018 FY	- USD	3.17%
2018 Q3	829.53 Million USD	0.0%
2018 Q1	625.51 Million USD	30.97%
2017 FY	- USD	1.92%
2017 Q1	604.91 Million USD	32.42%
2017 Q3	810.69 Million USD	0.0%
2017 Q4	477.61 Million USD	-41.09%
2016 FY	- USD	6.06%
2016 Q4	456.8 Million USD	-42.71%
2016 Q3	797.29 Million USD	0.0%
2016 Q1	604.9 Million USD	34.03%
2015 Q3	755.98 Million USD	0.0%
2015 Q1	576.24 Million USD	22.71%
2015 FY	- USD	6.8%
2015 Q4	451.31 Million USD	-40.3%
2014 FY	- USD	4.06%
2014 Q1	537.08 Million USD	22.2%
2014 Q3	709.18 Million USD	0.0%
2014 Q4	469.6 Million USD	-33.78%
2013 Q1	508.91 Million USD	37.58%
2013 Q4	439.49 Million USD	-37.8%
2013 FY	- USD	0.0%
2013 Q3	706.59 Million USD	0.0%
2012 Q4	369.91 Million USD	0.0%

Peer EBITDA Comparison of CrystalGenomics, Inc.

Name	EBITDA	EBITDA Difference
HLB Co., Ltd.	-172.27 Billion KRW	75.158%
iNtRON Biotechnology, Inc.	-6.23 Billion KRW	-586.44%
BINEX Co., Ltd.	10.87 Billion KRW	493.644%
Bioneer Corporation	10.04 Billion KRW	526.13%
Anterogen.Co.,Ltd.	-437.82 Million KRW	-9674.962%
MEDIPOST Co., Ltd.	-19.39 Billion KRW	-120.699%
Helixmith Co., Ltd	-53 Billion KRW	19.257%
Chabiotech Co.,Ltd.	70.08 Billion KRW	161.062%
Medy-Tox Inc.	32.69 Billion KRW	230.886%
Peptron, Inc.	-12.65 Billion KRW	-238.304%
Amicogen, Inc.	13.95 Billion KRW	406.72%
Genexine, Inc.	-40.87 Billion KRW	-4.695%
HLB Therapeutics Co.,Ltd.	8.22 Billion KRW	620.041%
LegoChem Biosciences, Inc.	-71.38 Billion KRW	40.047%
ALTEOGEN Inc.	440.04 Million KRW	9825.707%
PharmaResearch Co., Ltd.	104.25 Billion KRW	141.051%
SillaJen, Inc.	-17.35 Billion KRW	-146.635%
JETEMA, Co., Ltd.	11 Billion KRW	488.791%
OliX Pharmaceuticals,Inc	-11.13 Billion KRW	-284.346%
Genomictree Inc.	-6.33 Billion KRW	-575.905%
MedPacto, Inc.	-32.6 Billion KRW	-31.245%
D&D Pharmatech	-9.05 Billion KRW	-372.484%
EASY BIO,Inc.	24.32 Billion KRW	275.952%
GI Innovation, Inc.	-51.33 Billion KRW	16.624%